Lundbeck encourages publication of the results from research and discovery and from clinical studies of its products and drug development candidates, irrespective of whether the results are positive or negative, and acknowledges a special obligation to publish data related to patient safety.
Per EFPIA/PhRMA´s commitment, Lundbeck will submit for publication the results of all Lundbeck-sponsored phase III clinical studies and results of any other clinical studies of significant medical importance, primarily in peer-reviewed journals, or as abstracts, posters, or other presentations at scientific meetings. Publication activities will be undertaken responsibly and ethically to ensure that all relevant information is communicated clearly and in a timely manner. Wherever possible, manuscripts will be submitted no later than 18 months after study completion for approved products. This also applies to drug development compounds for which development has been discontinued.
The timing of nonclinical publications may take into consideration intellectual property rights as well as legislation and current national practices in patent law.
When entering into research and development collaborations, it is Lundbeck’s commitment to maintain ethical and transparent publication practices, which is in accordance with Good Publication Practice 3 (www.ismpp.org/gpp3).